ITI therapy has limited indications and a success rate of 63-80% [6] .
Patients with high-titer inhibitors and intractable bleeding episodes should be given recombinant activated factor VII (r-FVIIa) or activated prothrombin complex concentrate (aPCC), called the hemostatic bypassing agent (to circumvent FVIII in the coagulation pathway), as the first choice therapy. The FEIBA NovoSeven Comparative (FENOC) Study evaluated the hemostatic efficacy of both products on 96 joint bleeds of 48 inhibitor patients and showed nearly equivalent efficacy, with both agents being effective and safe, although a substantial number of patients reported different efficacies for both agents [7] . Nevertheless, 10-20% of bleeding events in hemophiliacs with high-titer inhibitors cannot be controlled by either r-FVIIa or aPCC alone and thus may need sequential combined bypassing therapy (SCBT).
The rationale for the use of a combination of r-FVIIa and aPCC is based on data from experiments using a rabbit stasis model, where an early thrombotic effect was shown, indicating the synergistic effect of both agents on thrombus formation during stasis [8] . Clinically, SCBT is predicated upon the fact that neither bypassing agent controls bleeding completely and the response of each individual patient to either agent differs [9] . These aspects were also observed in the FENOC study [7] , where up to 43.8% of subjects considered one product more effective than the other.
A recent study employing a comprehensive literature search revealed that a significant number of patients treated with SCBT experienced complications such as thrombosis: Editorial 5 of 9 patients with acquired hemophilia and 5 of 40 with congenital hemophilia, among which 4 cases were fatal [8] . Moreover, no randomized controlled study has been carried out to investigate SCBT. Hence, the sequential use of both bypassing agents should have strict indications as mentioned earlier and should be accompanied by a thorough follow up to assess for thrombosis, including disseminated intravascular coagulation.
In the current issue of Blood Research, Han and Park report their retrospective experience with the use of SCBT to treat 5 bleeds in 4 hemophilia A patients with high-titer inhibitors and refractoriness to both bypassing agents used individually [10] . The bleeds were associated with various clinical conditions: peripherally inserted central catheter (PICC) insertion, small bowel surgery, hemothorax, and 2 total knee replacements. Patients were treated by infusing aPCC every 8 or 12 hours with administration of 1 or 2 doses of r-FVIIa between the doses of aPCC (50-100 IU/kg aPCC and 90 μg/kg r-FVIIa). The dosage and intervals were similar to those used in previous studies [7] . Twelve-to 24-hour bleeding episodes were controlled satisfactorily with no thrombotic events associated with SCBT. Because there is a paucity of data on the treatment of high-titer inhibitor patients, this report contributes valuable information for the management of bleeding episodes in such patients in Korea. It is hoped that a prospective, randomized, and controlled study of SCBT will be carried out in Korea in the near future to overcome the limits of this retrospective study.
